Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011, for NeoStem, Inc. (Note: The input metadata referenced "Lisata Therapeutics," but the filing text identifies the registrant as NeoStem, Inc.). NeoStem is an international biopharmaceutical company operating in three segments: Cell Therapy (U.S.), Regenerative Medicine (China), and Pharmaceutical Manufacturing (China). The quarter was marked by the January 19, 2011, acquisition of Progenitor Cell Therapy, LLC ("PCT"), which significantly expanded the company's U.S. cell therapy capabilities and added an 80% interest in Athelos Corporation.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Revenues | $19,641,113 | $15,833,178 |
| Gross Profit | $5,346,477 | $4,981,560 |
| Gross Margin | 27.2% | 31.5% |
| Operating Loss | $(7,991,777) | $(2,608,296) |
| Net Loss | $(9,699,758) | $(3,283,832) |
| Net Loss Attributable to Common Shareholders | $(10,359,624) | $(4,712,183) |
| Loss Per Share (Basic & Diluted) | $(0.14) | $(0.12) |
| Cash and Cash Equivalents | $9,411,871 | $11,418,201 |
| Restricted Cash | $6,403,388 | $3,381,369 |
| Total Debt (Bank Loans, Notes, Mortgages) | $23,048,574 | Not directly comparable (Notes Payable $9.6M) |
| Working Capital | $9,488,565 | Not explicitly stated |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 24% to $19.6 million, driven primarily by the inclusion of PCT revenues ($1.4 million) and a 15% increase in Pharmaceutical Manufacturing (China) sales.
- Expense Surge: Operating expenses increased 75.7% to $13.3 million. Selling, General, and Administrative (SG&A) expenses rose $4.1 million due to PCT integration, increased legal/audit fees, and higher equity compensation. R&D expenses more than doubled to $2.9 million, largely due to a $927,000 write-off of in-process R&D related to an intellectual property acquisition from Becton Dickinson (BD) for the Athelos subsidiary.
- Debt and Liquidity: Notes payable increased significantly to $14.7 million (up from $9.6 million), supported by an increase in restricted cash collateral to $6.4 million. Cash and cash equivalents decreased by $6.2 million during the quarter.
- Segment Performance: The Pharmaceutical Manufacturing segment remained profitable with operating income of $2.1 million, while the Cell Therapy and Regenerative Medicine segments continued to incur operating losses.
Guidance, Outlook, and Risks
- Capital Requirements: Management anticipates a need for additional capital to fund cell therapy development, PCT expansion, and family banking initiatives. Funding sources may include existing cash, equity lines, warrant exercises, and potential asset sales (including a potential divestiture of the 51% interest in Erye).
- China Operations: Erye is relocating to a new facility with increased capacity, expected to be fully operational in 2011. However, the company faces price pressure on essential drugs in China, with potential price cuts of up to 50-75% on specific products.
- Legal Contingencies: Erye is involved in a patent infringement lawsuit regarding an antibiotic complex. A preliminary judgment awarded damages of approximately $750,000 to the plaintiff, which has been accrued. Erye has appealed, and the execution of the injunction was suspended as of March 2011.
- Preferred Stock Obligations: The company has Convertible Redeemable Series E Preferred Stock requiring monthly dividends and principal payments, which can be made in cash or stock. As of March 31, 2011, $6.4 million of this stock was outstanding.
- Internal Controls: A material weakness in accounting for share-based payments identified in 2010 has been remediated as of March 31, 2011.
Investor Verification Checklist
- Capital Adequacy: Verify the company's ability to meet liquidity needs given the $10.2 million net cash used in operating activities and the $6.4 million in restricted cash that is not available for general operations.
- Debt Covenants: Review the financial covenants associated with PCT's mortgage loans, noting that the company was not in compliance through December 2010 but obtained a waiver through June 30, 2011.
- China Price Controls: Assess the potential impact of government-mandated price cuts on Erye's key products (Piperacillin Sodium Sulbactam Sodium and Ligustrazine Phosphate) on future margins.
- Legal Exposure: Monitor the status of the patent infringement appeal and settlement negotiations involving Erye to determine if the accrued $750,000 liability will increase.
- Equity Dilution: Evaluate the dilution impact of outstanding warrants (25.1 million shares) and options (15.1 million shares), as well as the potential issuance of stock to satisfy Preferred Stock dividend obligations.